Pozen wins patent lawsuit, but full year outlook disappoints - Proactiveinvestors (NA)

Pharmaceutical company Pozen (NASDAQ:POZN) announced Tuesday it received a favourable verdict in its patent infringement lawsuit against several generic pharmaceutical companies, and announced a full year outlook below analysts' estimates. For the full year, Pozen said it expects revenues between $18 and $19 million, below analysts' $19.9 million estimate.